09:15 AM EDT, 10/27/2026 (MT Newswires) -- BofA Global Research is optimistic on Novartis' (NOVN.SW) growth after the Swiss pharmaceutical major delivered better-than-expected EPS in the third quarter and in-line sales figures. The company's core EPS rose 9% year over year to $2.46, beating consensus by 7%, the research firm said in a Tuesday note. Meanwhile, sales grew 4% to $14.5 billion, in line with market forecasts. Novartis also upgraded its full-year 2026 outlook for core operating income, while leaving its net sales guidance of low single-digit growth unchanged. "On newsflow, CMD (18th-19th Nov) confirming will roll forward existing 25-30E CAGR (at 5-6%) to 26-31E, we think likely above cons' c4% CAGR and we think include c5% in some form. We also see increase in key product peak guides (Scemblix/Leqvio/Pluvicto) & reiterate post-31 mid-sd% growth (we outline 3 areas of delta vs cons as existing launched assets remi and pipeline)," analysts said. "On2H26 pipeline: ianalumab 1L ITP & Rhapsido in HS in 2H26 unchanged, with Leqvio in CVRR-LDLC in ORION-4 now 4Q (prior FY27E). FY27: abelacimab in SPAF, Kesimpta Q2M, Zigakibart IgAN and ianalumab in lupus indications & SSc. Against this backdrop, the stock's buy rating was maintained, with a price objective of 150 francs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.